1. Scrip
  2. >>R&D
  3. >>Clinical Trials

Novartis’s Fabhalta Hits In Glomerulopathy But How Hard?

 
• By Elizabeth Cairns

So far, Novartis has only reported that its Phase III trial has succeeded and investors face a wait to find out just how good the drug is.  

Kidney

Last week, Novartis AG’s complement factor B inhibitor iptacopan scored an approval in paroxysmal nocturnal hemoglobinuria (PNH) under the name Fabhalta. Today it posted a different type of success, a clinical one, in the Phase III APPEAR-C3G in C3 glomerulopathy (C3G).

Key Takeaways
  • Full C3G data and filings could come next year
  • Fabhalta needs to show Phase III results at least as strong as its Phase II data
  • Apellis’s Empaveli is not far

The hit suggests that Novartis may have, as it hopes, a pipeline in a product – Fabhalta had a late-stage hit in another kidney disorder, IgA nephropathy (IgAN), in October

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

More from R&D

Pipeline Watch: Six Approvals And Thirteen Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Viatris Will File ‘Fast-Acting’ Meloxicam For FDA Approval This Year

 
• By Joseph Haas

Seven years after acquiring it, Viatris will seek approval of a meloxicam formulation for acute pain backed by data from two Phase III studies in post-surgical pain settings.

CRISPR Therapeutics Unveils Promising Early In Vivo Cholesterol-Lowering Results

 
• By Andrew McConaghie

The Phase I results are the best to date among ANGPTL3-targeting candidates in the pipeline, but analysts will wait for further updates before predicting a likely winner.